ESMO 2026 Presidential Symposium III: ADC and immunotherapy highlights from the the ARTEMIS-011, TroFuse-005, KEYNOTE-C93, and MOIO trials.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
BLA Submitted for Etentamig in Relapsed/Refractory Myeloma
2
Elranatamab Improves PFS in Relapsed/Refractory Multiple Myeloma
3
TroFuse-005: Dr Pothuri on Sac-TMT in Advanced Endometrial Cancer
4
Enzomenib Earns FDA Breakthrough Status in KMT2A-Rearranged Leukemia
5